ABC 131
Alternative Names: ABC131Latest Information Update: 28 Nov 2021
At a glance
- Originator Apogee Biotechnology Corporation
- Class Antineoplastics; Thiazoles
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 29 Oct 2017 Pharmacodynamics, pharmacokinetic and adverse events data from a preclinical trial in cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
- 29 Oct 2017 Preclinical trials in Cancer in USA (PO)